Dragan Sebisanovic

2.6k total citations · 2 hit papers
13 papers, 2.0k citations indexed

About

Dragan Sebisanovic is a scholar working on Cancer Research, Pathology and Forensic Medicine and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Dragan Sebisanovic has authored 13 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Cancer Research, 6 papers in Pathology and Forensic Medicine and 6 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Dragan Sebisanovic's work include Cancer Genomics and Diagnostics (12 papers), Genetic factors in colorectal cancer (6 papers) and Lung Cancer Treatments and Mutations (5 papers). Dragan Sebisanovic is often cited by papers focused on Cancer Genomics and Diagnostics (12 papers), Genetic factors in colorectal cancer (6 papers) and Lung Cancer Treatments and Mutations (5 papers). Dragan Sebisanovic collaborates with scholars based in United States, South Korea and Switzerland. Dragan Sebisanovic's co-authors include Jeremy Stinson, Somasekar Seshagiri, David A. Ramies, Bruce E. Johnson, Vincent A. Miller, Sherry Heldens, William L. Ince, Thomas Januario, Lukas C. Amler and Kenneth J. Hillan and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Nature Methods.

In The Last Decade

Dragan Sebisanovic

12 papers receiving 1.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Mutations in the Epidermal Growth Factor Receptor and in KRAS Are Predictive and Prognostic Indicators in Patients With Non–Small-Cell Lung Cancer Treated With Chemotherapy Alone and in Combination With Erlotinib

2005 1.2k citations David A. Eberhard, Bruce E. Johnson et al. Journal of Clinical Oncology profile →
Analytical and Clinical Validation of a Digital Sequencing Panel for Quantitative, Highly Accurate Evaluation of Cell-Free Circulating Tumor DNA

2015 470 citations Richard B. Lanman, Stefanie Mortimer et al. PLoS ONE profile →

Peers

Countries citing papers authored by Dragan Sebisanovic

Since Specialization

Citations

This map shows the geographic impact of Dragan Sebisanovic's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dragan Sebisanovic with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dragan Sebisanovic more than expected).

Fields of papers citing papers by Dragan Sebisanovic

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dragan Sebisanovic. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dragan Sebisanovic. The network helps show where Dragan Sebisanovic may publish in the future.

Co-authorship network of co-authors of Dragan Sebisanovic

This figure shows the co-authorship network connecting the top 25 collaborators of Dragan Sebisanovic. A scholar is included among the top collaborators of Dragan Sebisanovic based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dragan Sebisanovic. Dragan Sebisanovic is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

13 of 13 papers shown

#	Work	Indexed citations
1	Cell-Free DNA Next-Generation Sequencing in Pancreatobiliary Carcinomas 2015 ·Cancer Discovery ·Oliver A. Zill, Claire Greene, Dragan Sebisanovic, (unknown), Jim Leng, Mary Vu, Andrew Hendifar, Zhen Wang, Chloé E. Atreya, Robin Kate Kelley, Katherine Van Loon, Andrew H. Ko, Margaret A. Tempero, Trever G. Bivona, Pamela N. Münster, AmirAli Talasaz, Eric A. Collisson	202
2	Analytical and Clinical Validation of a Digital Sequencing Panel for Quantitative, Highly Accurate Evaluation of Cell-Free Circulating Tumor DNA breakdown → 2015 ·PLoS ONE ·Richard B. Lanman, Stefanie Mortimer, Oliver A. Zill, Dragan Sebisanovic, René López, Sibel Blau, Eric A. Collisson, Stephen G. Divers, Dave S.�B. Hoon, Scott Kopetz, Jeeyun Lee, Petros Nikolinakos, Arthur M. Baca, Bahram G. Kermani, Helmy Eltoukhy, AmirAli Talasaz	470
3	Abstract 2403: Biopsy-free comprehensive tumor profiling of 1,000+ consecutive cancer patients using CLIA-certified commercial test and its clinical utility 2015 ·Cancer Research ·Eric A. Collisson, Stefanie Mortimer, Dragan Sebisanovic, Reza Bayat Mokhtari, Somayeh Bakhtiari, René López, (unknown), (unknown), Heena Patel, Bahram G. Kermani, Helmy Eltoukhy, Richard B. Lanman, AmirAli Talasaz	1
4	Abstract P2-04-03: Circulating tumor DNA (ctDNA) provides molecular monitoring for inflammatory breast cancer (IBC) 2015 ·Cancer Research ·Laura Austin, Paolo Fortina, Dragan Sebisanovic, (unknown), (unknown), Benjamin J. Schiller, Gangwu Mei, Helmy Eltoukhy, AmirAli Talasaz, Massimo Cristofanilli	1
5	Abstract 4928: Clinical utility of circulating tumor DNA (ctDNA) in advanced and metastatic breast cancer 2015 ·Cancer Research ·(unknown), Rebecca Jaslow, (unknown), Paolo Fortina, Dragan Sebisanovic, (unknown), (unknown), AmirAli Talasaz, Massimo Cristofanilli	0
6	Identification of multiple informative genomic mutations by deep sequencing of circulating cell-free tumor DNA in plasma of metastatic melanoma patients. 2014 ·Journal of Clinical Oncology ·Dave S.�B. Hoon, Sharon K. Huang, Dragan Sebisanovic, (unknown), (unknown), Stefanie Mortimer, AmirAli Talasaz	3
7	Circulating tumor DNA (ctDNA) as a molecular monitoring tool in metastatic breast cancer (MBC). 2014 ·Journal of Clinical Oncology ·(unknown), Paolo Fortina, Dragan Sebisanovic, (unknown), (unknown), AmirAli Talasaz, Massimo Cristofanilli	4
8	Ultra-high-quality sequencing assay for comprehensive genetic panel analysis of tumor-derived circulating cell-free DNA in colorectal cancer patients. 2014 ·Journal of Clinical Oncology ·Jeeyun Lee, Stefanie Mortimer, Gangwu Mei, Dragan Sebisanovic, (unknown), Helmy Eltoukhy, AmirAli Talasaz	2
9	Frequency of concurrent gene mutations and copy number alterations in circulating cell-free DNA (cfDNA) from refractory metastatic CRC patients. 2014 ·Journal of Clinical Oncology ·Maria Pia Morelli, Michael J. Overman, (unknown), Van K. Morris, Imad Shureiqi, Chris R. Garrett, David R. Fogelman, Kanwal Raghav, Bryan K. Kee, (unknown), Cathy Eng, Robert A. Wolff, Dragan Sebisanovic, (unknown), (unknown), Gangwu Mei, (unknown), Helmy Eltoukhy, AmirAli Talasaz, Scott Kopetz	6
10	Use of the GUARDANT360 noninvasive tumor sequencing assay on 300 patients across colorectal, melanoma, lung, breast, and prostate cancers and its clinical utility. 2014 ·Journal of Clinical Oncology ·AmirAli Talasaz, Stefanie Mortimer, Dragan Sebisanovic, (unknown), (unknown), Gangwu Mei, (unknown), Helmy Eltoukhy	9
11	Distinguishing Cancer-Associated Missense Mutations from Common Polymorphisms 2007 ·Cancer Research ·Joshua S. Kaminker, Yan Zhang, (unknown), Peter M. Haverty, Brock A. Peters, Dragan Sebisanovic, Jeremy Stinson, William F. Forrest, J. Fernando Bazán, Somasekar Seshagiri, Zemin Zhang	104
12	Highly efficient somatic-mutation identification using Escherichia coli mismatch-repair detection 2007 ·Nature Methods ·Brock A. Peters, Zhengyan Kan, Dragan Sebisanovic, Kanan Pujara, Zhiyong Wang, (unknown), Bernard Chow, Jeremy Stinson, Victoria Carlton, Thinh Q. Pham, Howard M. Stern, Paul Waring, Kenneth J. Hillan, David A. Eberhard, Frédéric J. de Sauvage, Jianbiao Zheng, Malek Faham, Somasekar Seshagiri	5
13	Mutations in the Epidermal Growth Factor Receptor and in KRAS Are Predictive and Prognostic Indicators in Patients With Non–Small-Cell Lung Cancer Treated With Chemotherapy Alone and in Combination With Erlotinib breakdown → 2005 ·Journal of Clinical Oncology ·David A. Eberhard, Bruce E. Johnson, Lukas C. Amler, Audrey D. Goddard, Sherry Heldens, Roy S. Herbst, William L. Ince, Pasi A. Jänne, Thomas Januario, David H. Johnson, Pam Klein, Vincent A. Miller, (unknown), David A. Ramies, Dragan Sebisanovic, Jeremy Stinson, (unknown), Somasekar Seshagiri, Kenneth J. Hillan	1200

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact